Real-world Treatment Patterns and Effectiveness Among Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Real-world Progression Free Survival (rwPFS)
研究概览
简要总结
Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bladder cancer that has spread outside the bladder is called advanced or metastatic bladder cancer.
The purpose of this study is to examine how long it takes for adults with advanced or metastatic bladder cancer to experience worsening of their disease following their first treatment . The researchers will also describe which medicines these patients use as their first treatment for the disease.
This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database who:
- Were identified to have advanced or metastatic bladder cancer.
- Started their first treatment after 01 Apr 2023.
- Were 18 years of age or older when they were diagnosed with advanced disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (18 years or older) diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Flatiron Health database.
- •Started first line systemic treatment for la/mUC during the study period.
- •Received care in the United States, as the study is U.S.-based.
- •Has sufficient available real-world data to assess treatment patterns and outcomes (e.g., treatment dates, follow-up, response/survival information).
排除标准
- •Histology other than transitional cell (urothelial) carcinoma.
- •Primary site of disease other than bladder, renal pelvis, ureter, or urethra
- •Clinical trial participation.
研究组 & 干预措施
la/mUC
Patients with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who received first line treatment.
结局指标
主要结局
Real-world Progression Free Survival (rwPFS)
时间窗: Up to 2 Years
Time from initiation of first line treatment for la/mUC to the earliest of disease progression or death, based on real-world data sources.
次要结局
- Real-world Overall Tumor Response (rwOTR)(Up to 2 Years)